Will Breyanzi's Label Expansion Boost BMY's CAR T Cell Therapy Sales?

Key Takeaways Bristol Myers gained FDA approval to extend Breyanzi's use to relapsed or refractory MZL.Breyanzi is now the only FDA-approved CAR T therapy covering five cancer types.Breyanzi sales reached $966M in the first nine months of 2025 on strong U.S. and international demand.Bristol Myers Squibb (BMY) recently obtained FDA approval for the label expansion of Breyanzi (lisocabtagene maraleucel) for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) who have ...